Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.33 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224025 | 1.00 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1OPRM1OPRL1OPRK1 | |
| SCHEMBL5204555 | 1.00 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1OPRM1OPRL1OPRK1 | |
| SCHEMBL8221542 | 0.83 | CHRM1 (0.45) | L3MBTL1OPRM1OPRL1GAA | |
| SCHEMBL1929499 | 0.83 | CHRM1 (0.45) | L3MBTL1OPRM1OPRL1GAA | |
| SCHEMBL1928769 | 0.83 | CHRM1 (0.45) | L3MBTL1OPRM1OPRL1GAA | |
| SCHEMBL12547129 | 0.83 | OPRM1 (0.40) | L3MBTL3L3MBTL1OPRM1OPRL1OPRK1 | |
| SCHEMBL3409132 | 0.80 | L3MBTL3 (0.36) | L3MBTL3L3MBTL1OPRM1OPRL1OPRK1 | |
| SCHEMBL1928713 | 0.78 | CHRM2 (0.42) | L3MBTL3OPRM1OPRL1OPRK1MBTD1 | |
| SCHEMBL1929516 | 0.78 | OPRM1 (0.45) | OPRM1OPRK1 | |
| SCHEMBL1929062 | 0.78 | CHRM1 (0.53) | L3MBTL1OPRM1OPRL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| WO-2007142583-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287695-A1 | Novel Compounds | OPRM1, OPRL1, OPRK1 | L3MBTL3 1341/4885L3MBTL1 1464/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.